The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ENGN | +49.53% | N/A | N/A | -4% |
| S&P | +14.77% | +87.2% | +13.35% | +52% |
enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$171.00K | -106.0% |
| Market Cap | $369.09M | -5.7% |
| Market Cap / Employee | $4.50M | 0.0% |
| Employees | 82 | 43.9% |
| Net Income | -$37,880.00K | -147.6% |
| EBITDA | -$39,310.00K | -126.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $50.15M | -71.0% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $21.78M | -8.9% |
| Short Term Debt | $10.02M | 792.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -44.05% | 0.0% |
| Return On Invested Capital | -35.26% | 5.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$25,399.00K | -28.2% |
| Operating Free Cash Flow | -$24,962.00K | -27.6% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.25 | 0.84 | 0.85 | 1.84 | 8.08% |
| Price to Tangible Book Value | 1.25 | 0.84 | 0.85 | 1.84 | 8.08% |
| Enterprise Value to EBITDA | -5.76 | -0.71 | -0.77 | -5.29 | -50.56% |
| Return on Equity | -44.2% | -34.0% | -44.0% | -53.3% | - |
| Total Debt | $25.13M | $25.36M | $31.38M | $31.80M | 27.07% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
